Boston Scientific said on Tuesday it will buy Silk Road Medical, a medical device company treating stroke, for $1.16 billion.
Silk Road Medical sells technology meant to prevent stroke in patients with carotid artery disease, a condition creating blockages in the major blood vessels connected to the brain. The company’s core products enable a procedure that temporarily sends blood flow away from the brain to prevent plaque from blocking the vessel. Doctors then implant a stent to widen the artery.
Silk Road Medical’s devices are the only commercially available products for this specific procedure, called transcarotid artery revascularization. The technology earned Food and Drug Administration approval in 2015. Other big players in the vascular device world are LeMaitre Vascular and Baxter.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect